Treatment interruption in hypertensive patients during the COVID-19 pandemic: An interrupted time series analysis using prescription data in Okayama, Japan.

COVID‐19 antihypertensive agents health behavior interrupted time series analysis prescription drugs treatment interruption

Journal

Journal of general and family medicine
ISSN: 2189-7948
Titre abrégé: J Gen Fam Med
Pays: Japan
ID NLM: 101689875

Informations de publication

Date de publication:
Mar 2024
Historique:
received: 13 09 2023
revised: 28 01 2024
accepted: 09 02 2024
medline: 14 3 2024
pubmed: 14 3 2024
entrez: 14 3 2024
Statut: epublish

Résumé

The COVID-19 pandemic has impacted healthcare behaviors, leading to fewer pediatric visits in Japan and potentially fewer visits by adult patients. However, existing Japanese studies on treatment interruptions have generally relied on questionnaire-based methods. In this study, we assessed the impact of the pandemic on antihypertensive treatment interruption using real-world prescription data. We conducted an interrupted time series analysis using the National Health Insurance Database in Okayama Prefecture, Japan. Participants included individuals aged 40-69 years with at least one antihypertensive prescription between 2018 and 2020. Treatment interruption was defined as a 3-month or longer gap in prescriptions after medication depletion. We used segmented Poisson regression with models unadjusted and adjusted for seasonality and over-dispersion to assess monthly treatment interruptions before and after Japan's April 2020 emergency. During the study period, 23.0% of 55,431 participants experienced treatment interruptions. Cyclical fluctuations in interruptions were observed. The crude analysis indicated a 1.2-fold increase in treatment interruptions following the pandemic; however, the adjusted models showed no significant changes. Even among higher-risk groups, such as women, younger adults, and those with shorter prescriptions, no significant alterations were observed. We found no significant impact of the COVID-19 pandemic on antihypertensive treatment interruption in Okayama Prefecture. The less severe outbreak in the area or increased use of telemedicine and extended prescriptions may have contributed to treatment continuity. Further research is needed using a more stable and comprehensive database, broader regional data, and detailed prescription records to validate and extend our findings.

Sections du résumé

Background UNASSIGNED
The COVID-19 pandemic has impacted healthcare behaviors, leading to fewer pediatric visits in Japan and potentially fewer visits by adult patients. However, existing Japanese studies on treatment interruptions have generally relied on questionnaire-based methods. In this study, we assessed the impact of the pandemic on antihypertensive treatment interruption using real-world prescription data.
Methods UNASSIGNED
We conducted an interrupted time series analysis using the National Health Insurance Database in Okayama Prefecture, Japan. Participants included individuals aged 40-69 years with at least one antihypertensive prescription between 2018 and 2020. Treatment interruption was defined as a 3-month or longer gap in prescriptions after medication depletion. We used segmented Poisson regression with models unadjusted and adjusted for seasonality and over-dispersion to assess monthly treatment interruptions before and after Japan's April 2020 emergency.
Results UNASSIGNED
During the study period, 23.0% of 55,431 participants experienced treatment interruptions. Cyclical fluctuations in interruptions were observed. The crude analysis indicated a 1.2-fold increase in treatment interruptions following the pandemic; however, the adjusted models showed no significant changes. Even among higher-risk groups, such as women, younger adults, and those with shorter prescriptions, no significant alterations were observed.
Conclusion UNASSIGNED
We found no significant impact of the COVID-19 pandemic on antihypertensive treatment interruption in Okayama Prefecture. The less severe outbreak in the area or increased use of telemedicine and extended prescriptions may have contributed to treatment continuity. Further research is needed using a more stable and comprehensive database, broader regional data, and detailed prescription records to validate and extend our findings.

Identifiants

pubmed: 38481745
doi: 10.1002/jgf2.678
pii: JGF2678
pmc: PMC10927915
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102-109

Informations de copyright

© 2024 The Authors. Journal of General and Family Medicine published by John Wiley & Sons Australia, Ltd on behalf of Japan Primary Care Association.

Déclaration de conflit d'intérêts

This work was partly supported by funding from the commissioned project budget “FY2021 National Health Insurance Health‐Up Support Project,” provided by Okayama Prefecture. The sponsors were not involved in the study design; the collection, analysis, and interpretation of data; the writing of the report; or the decision to submit the article for publication.

Auteurs

Naoko Nakamura (N)

Department of Epidemiology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.

Toshiharu Mitsuhashi (T)

Center for Innovative Clinical Medicine Okayama University Hospital Okayama Japan.

Naomi Matsumoto (N)

Department of Epidemiology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.

Shunsaku Hayase (S)

Academic Affairs Division Okayama University Okayama Japan.

Takashi Yorifuji (T)

Department of Epidemiology Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Okayama Japan.

Classifications MeSH